EMA/627033/2015

European Medicines Agency decision

P/0236/2015

of 30 October 2015

on the acceptance of a modification of an agreed paediatric investigation plan for everolimus, (Votubia) (EMEA-000019-PIP08-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0236/2015

of 30 October 2015

on the acceptance of a modification of an agreed paediatric investigation plan for everolimus, (Votubia) (EMEA-000019-PIP08-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0012/2013 issued on 23 January 2013,

Having regard to the application submitted by Novartis Europharm Limited on 10 June 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 September 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and a refusal of the changes to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan and a refusal of changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for everolimus, (Votubia), tablet, dispersible tablet, oral use, refusing changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Frimley Business Park, GU16 7SR – Camberley, United Kingdom.

Done at London, 30 October 2015

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature of file)

EMA/PDCO/453892/2015 corr
London, 11 September 2015

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000019-PIP08-12-M01

Scope of the application

Active substance(s):

Everolimus

Invented name:

Votubia

Condition(s):

Treatment of Tuberous Sclerosis Complex

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Dispersible tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 10 June 2015 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0012/2013 issued on 23 January 2013.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 14 July 2015.

Scope of the modification

A timeline of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to refuse a change to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition: Treatment of Tuberous Sclerosis Complex

2.1.1. Indication(s) targeted by the PIP

Treatment of refractory epilepsy associated with Tuberous Sclerosis Complex (TSC)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Dispersible tablet

2.1.4. Studies

Area	Number of measures	Description
Quality	1	Measure 1: Development of dispersible tablet for oral use, including strengths of 2 mg, 3 mg and 5 mg
Non-clinical	0	Not applicable
Clinical	2	Measure 2: Randomised, double blind placebo controlled, two trough ranges, multicentre, trial to evaluate efficacy, safety, pharmacokinetics, of everolimus as adjunctive therapy in children from 1 year to less than 18 years of age (and adults) in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures Measure 3: Randomized, placebo controlled, multicentre, study to evaluate the safety, tolerability, pharmacokinetics and efficacy of everolimus dispersible tablets in children from birth to less than 2 years of age with tuberous sclerosis complex (TSC) and infantile spasms

The date of completion of the paediatric investigation plan corresponds to the timeline for completion of the latest measure(s) reported below.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of tuberous sclerosis complex (TSC)

Authorised indication(s):

- Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)

  Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.

  The evidence is based on analysis of change in sum of angiomyolipoma volume.

- Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)

  Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.

  The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease related symptoms, has not been demonstrated.

Authorised pharmaceutical formulation(s):

Tablet and Dispersible Tablet

Authorised route(s) of administration:

Oral use